Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb

Life Sciences

Volumn 80, Issue 20, 2007, Pages 1906-1914

  Franco, Jeferson ^a   Prediger, Rui D S ^a   Pandolfo, Pablo ^a   Takahashi, Reinaldo N ^a   Farina, Marcelo ^a   Dafre, Alcir L ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Glutamyl transpeptidase; Glutathione; Lipid peroxidation; MPTP; Oxidative stress; Parkinson's disease; Rat

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; LIPID; NEUROTOXIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; NERVE DEGENERATION; NONHUMAN; OLFACTORY BULB; OLFACTORY SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PREFRONTAL CORTEX; PRIMATE; RAT; RODENT; SUBSTANTIA NIGRA; TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LIPID PEROXIDATION; MALE; OLFACTORY BULB; RATS; RATS, WISTAR; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

PRIMATES; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 34147171111     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.02.021     Document Type: Article

References (51)

1. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature reviews. Neuroscience 7 3 (2006) 207-219
2. Akerboom T.P., and Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods in Enzymology 77 (1981) 373-382
3. Andreassen O.A., Ferrante R.J., Dedeoglu A., Albers D.W., Klivenyi P., Carlson E.J., Epstein C.J., and Beal M.F. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Experimental Neurology 167 1 (2001) 189-195
4. Arumugam T.V., Gleichmann M., Tang S.C., and Mattson M.P. Hormesis/preconditioning mechanisms, the nervous system and aging. Ageing Research Reviews 5 2 (2006) 165-178
5. Barnett E.M., and Perlman S. The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM. Virology 194 1 (1993) 185-191
6. Braak H., Ghebremedhin E., Rub U., Bratzke H., and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell and Tissue Research 318 1 (2004) 121-134
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 1-2 (1976) 248-254
8. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National Academy of Sciences of the United States of America 80 14 (1983) 4546-4550
9. + in the rat. Neuroscience Letters 118 2 (1990) 151-154
10. Carlberg I., and Mannervik B. Glutathione reductase. Methods in Enzymology 113 (1985) 484-490
11. Chemuturi N.V., Haraldsson J.E., Prisinzano T., and Donovan M. Role of dopamine transporter (DAT) in dopamine transport across the nasal mucosa. Life Sciences 79 14 (2006) 1391-1398
12. Chinta S.J., Rajagopalan S., Butterfield D.A., and Andersen J.K. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neuroscience Letters 402 1-2 (2006) 137-141
13. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Pert A., and Kopin I.J. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. European Journal of Pharmacology 100 2 (1984) 189-194
14. Cunha C., Angelucci M.E., Canteras N.S., Wonnacott S., and Takahashi R.N. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cellular and Molecular Neurobiology 22 3 (2002) 227-237
15. Dluzen D.E., and Kefalas G. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice. Brain Research 741 1-2 (1996) 215-219
16. Doty R.L., Bromley S.M., and Stern M.B. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 4 1 (1995) 93-97
17. Dringen R., Pfeiffer B., and Hamprecht B. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. Journal of Neuroscience 19 2 (1999) 562-569
18. Giovanni A., Sieber B.A., Heikkila R.E., and Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. The Journal of Pharmacology and Experimental Therapeutics 270 3 (1994) 1000-1007
19. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., and Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50 5 (1998) 1346-1350
20. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Experimental Neurology 193 2 (2005) 279-290
21. Hastings L., and Evans J.E. Olfactory primary neurons as a route of entry for toxic agents into the CNS. Neurotoxicology 12 4 (1991) 707-714
22. Hawkes C.H., Shephard B.C., and Daniel S.E. Is Parkinson's disease a primary olfactory disorder?. QJM: QJM: An International Journal of Medicine 92 8 (1999) 473-480
23. Hirrlinger J., Schulz J.B., and Dringen R. Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease. Journal of Neurochemistry 82 3 (2002) 458-467
24. Hung H.C., and Lee E.H. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radical Biology & Medicine 24 1 (1998) 76-84
25. Kalaria R.N., Mitchell M.J., and Harik S.I. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proceedings of the National Academy of Sciences of the United States of America 84 10 (1987) 3521-3525
26. Kawano T., and Margolis F.L. Transsynaptic regulation of olfactory bulb catecholamines in mice and rats. Journal of Neurochemistry 39 2 (1982) 342-348
27. Klivenyi P., St Clair D., Wermer M., Yen H.C., Oberley T., Yang L., and Flint Beal M. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiology of Disease 5 4 (1998) 253-258
28. Klivenyi P., Andreassen O.A., Ferrante R.J., Dedeoglu A., Mueller G., Lancelot E., Bogdanov M., Andersen J.K., Jiang D., and Beal M.F. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Journal of Neuroscience 20 1 (2000) 1-7
29. Kumar R., Agarwal A.K., and Seth P.K. Oxidative stress-mediated neurotoxicity of cadmium. Toxicology Letters 89 1 (1996) 65-69
30. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 4587 (1983) 979-980
31. Leret M.L., San Millan J.A., Fabre E., Gredilla R., and Barja G. Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. Toxicology 170 3 (2002) 165-171
32. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nature Reviews. Neuroscience 3 12 (2002) 932-942
33. Marzatico F., Cafe C., Taborelli M., and Benzi G. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Neurochemical Research 18 10 (1993) 1101-1106
34. Meister A., Tate S.S., and Griffith O.W. Gamma-glutamyl transpeptidase. Methods in Enzymology 77 (1981) 237-253
35. Odunze I.N., Klaidman L.K., and Adams Jr. J.D. MPTP toxicity in the mouse brain and vitamin E. Neuroscience Letters 108 3 (1990) 346-349
36. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 95 2 (1979) 351-358
37. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience 22 (1999) 123-144
38. Perry T.L., Godin D.V., and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neuroscience Letters 33 3 (1982) 305-310
39. Perry T.L., Yong V.W., Clavier R.M., Jones K., Wright J.M., Foulks J.G., and Wall R.A. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neuroscience Letters 60 2 (1985) 109-114
40. Prediger R.D., Batista L.C., Medeiros R., Pandolfo P., Florio J.C., and Takahashi R.N. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Experimental Neurology 202 2 (2006) 391-403
41. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., and Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Journal of Neuroscience 12 5 (1992) 1658-1667
42. Rojo A.I., Montero C., Salazar M., Close R.M., Fernandez-Ruiz J., Sanchez-Gonzalez M.A., de Sagarra M.R., Jackson-Lewis V., Cavada C., and Cuadrado A. Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. European Journal of Neuroscience 24 7 (2006) 1874-1884
43. Sechi G., Deledda M.G., Bua G., Satta W.M., Deiana G.A., Pes G.M., and Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 20 7 (1996) 1159-1170
44. Shi Z., Zhang Q., and Jiang X. Pharmacokinetic behavior in plasma, cerebrospinal fluid and cerebral cortex after intranasal administration of hydrochloride meptazinol. Life Sciences 77 20 (2005) 2574-2583
45. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology 36 3 (1994) 348-355
46. Sriram K., Pai K.S., Boyd M.R., and Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Research 749 1 (1997) 44-52
47. Tjalve H., Henriksson J., Tallkvist J., Larsson B.S., and Lindquist N.G. Uptake of manganese and cadmium from the nasal mucosa into the central nervous system via olfactory pathways in rats. Pharmacology and Toxicology 79 6 (1996) 347-356
48. Uversky V.N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell and Tissue Research 318 1 (2004) 225-241
49. Wendel A. Glutathione peroxidase. Methods in Enzymology 77 (1981) 325-333
50. Zatta P., Favarato M., and Nicolini M. Deposition of aluminum in brain tissues of rats exposed to inhalation of aluminum acetylacetonate. Neuroreport 4 9 (1993) 1119-1122
51. Zhang J., Graham D.G., Montine T.J., and Ho Y.S. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. Journal of Neuropathology and Experimental Neurology 59 1 (2000) 53-61